Process Development and Scale-Up of RLY-2139: A Selective CDK2 Inhibitor Targeting ER+/HER2– Breast Cancer

已完结 10 由哈哈哈哈发布于 2026/4/13 14:40:49

DOI:10.1021/acs.oprd.5c00342
作者：Seema Bag,?, ,?Allen Qinglin Che,?, ,?Andre Lescarbeau,?, ,?Daniel Jones,?, ,?Vishnu Karnati,?, ,?Jing He,?, ,?Alexander Merton Taylor,?, ,?Charles Heap,?, ,?Tim Briggs,?, ,?Jianglin Colin Liang,?, ,?
文献类型：期刊论文
补充材料：只需要正文

American Chemical Society (ACS)

Abstract：RLY-2139 is a potent and selective orthosteric CDK2/Cyclin E inhibitor in development for the treatment of ER+/HER2– breast cancer. It showed an on target IC50 of 4 nM for CDK2/CycE and good

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:American Chemical Society (ACS)Aggregation of Nanoplastics via Eco-corona Formation and Hetero-Aggregation in Soil Solution